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Abstract. Acinetobacter baumannii is an important opportunistic pathogen, responsible for 
approximately 10% of all gram-negative nosocomial infection. The aim of this study was to 
determine aminoglycoside and quinolone resistance genes and their antimicrobial susceptibility 
profile in the clinically A. baumannii. In this cross-sectional study, a total of 100 nonduplicative 
A. baumannii isolates were collected from different clinical samples. Antimicrobial susceptibility 
test was performed by disk diffusion method. QnrA, anrB, qnrS, aac(3)-IIa, and aac(6′)-Ib genes 
were identified using PCR method. The results of antibiotic susceptibility test showed that 
polymyxin B was the most effective antimicrobial against A. baumannii. 97%, 95% and 82% of 
isolates were resistant to cefepime, ceftriaxone, and amikacin, respectively. The molecular 
distribution of aac(3)-IIa, aac(6′)-Ib, and qnrA genes were 45%, 50%, and 50% of isolates, 
respectively. However, qnrB and qnrS genes could not be detected in any strain. This study 
showed that polymyxin B was the best drug against A. baumannii clinical isolates. This data is 
also valid for polymyxin E (colistin), which is mostly used in clinics. There is a high level of 
resistance genes among clinical A. baumannii isolates. This high prevalence rate highlights the 
necessity for the development of rapid diagnostic assays and continuous monitoring of antibiotic 
resistance. 
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Introduction. Acinetobacter baumannii is a 
lactose non-fermenting gram-negative bacillus 
(NF-GNB) that has emerged as a highly 
troublesome pathogen particularly in critically ill 
patients.
1
 Clinical isolates of A. baumannii are 
responsible for pulmonary, device-related, 
bloodstream, and urinary tract infections and are 
frequently isolated from hospitalized ICU 
patients.
2
 These isolates were associated with 
multiple antibiotic resistance, and the spread of 
drug-resistant A. baumannii strains among 
hospitalized patients have become an increasing 
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public health threat.
3,4
 Furthermore, due to the 
intrinsic resistance mechanisms in this 
opportunistic nosocomial pathogen, it is quicker to 
become multidrug-resistant (MDR).
5
 
Polymyxin B and polymyxin E (colistin), are an 
increasingly significant part of the antimicrobial 
agents against MDR gram-negative bacteria. 
These two drugs have the same spectrum and are 
appropriate for use in the clinical settings.
6,7
 At 
present in Europe in the patients with MDR A. 
baumannii the clinician utilize the colistin, and in 
the future, it is possible using the new derivatives.
8
 
Aminoglycosides are used most commonly in 
the treatment of life-threatening infections caused 
by A. baumannii strains.
9
 The efflux pumps, 
decreased outer membrane permeability, amino 
acid substitutions and enzymatic modification, are 
the main mechanisms of aminoglycoside 
resistance in these bacteria.
10 Enzymatic 
modification is the most common type of 
aminoglycoside resistance in A. baumannii clinical 
isolates and usually results in high-level drug 
resistance.
11
 Most enzyme-mediated resistance in 
A. baumannii is due to the genes encoding for 
aminoglycoside-modifying enzymes (AMEs) 
which found on plasmids and transposons. Three 
types of AMEs include N-acetyltransferases 
(AAC), O-adenyltransferases (ANT), and O-
phosphotransferases (APH).
12,13
 
The plasmid-mediated quinolone resistance 
(PMQR) genes, such as qnrA, qnrB, and qnrS, are 
responsible for quinolone resistance in A. 
baumannii isolates. PMQRs were first detected in 
the 1990s as a plasmid gene in Klebsiella 
pneumonia clinical isolates. Subsequent studies 
have shown that qnr genes have a worldwide 
distribution in a range of Gram-negative 
opportunist pathogens. Although the qnr 
expression mechanism which confers clinical 
quinolone resistance is the least understood, the 
DNA topoisomerase protection protein Qnr 
protects DNA from quinolone binding and causes 
resistance to quinolones.
14-16
 The prevalence of 
quinolone- and/or aminoglycoside-resistant A. 
baumannii was increased during the past decade. 
The present study was carried out to investigate 
antibiotic resistance pattern and resistance-related 
genes such as qnrA, anrB, qnrS, aac(3)-IIa, and 
aac(6′)-Ib in A. baumannii clinical isolates by 
polymerase chain reaction (PCR) assay. 
 
Materials and Methods. The current study was a 
cross-sectional descriptive research which 
conducted from February 2015 to April 2016, at 
two teaching hospitals (Baqiyatallah and Moheb 
mehr hospitals) in Tehran, Iran. One hundred non-
repetitive strains of A. baumannii were obtained 
from different clinical specimens, including 
tracheal secretion, blood, wound, urine, and other 
samples. The isolates were identified using well-
recognized biochemical tests such as Gram 
staining, oxidative/fermentative glucose test, 
catalase test, motility, oxidase test, citrate 
utilization, and capability to grow at 42–44°C.17 
Species identification was confirmed by detection 
of blaOXA-51-like genes, as described 
previously.
18
 All strains were preserved in Luria–
Bertani broth (Merck Co., Germany) containing 
20% glycerol (v/v) at –80°C for further use. 
Antimicrobial susceptibility was carried out on 
the Mueller-Hinton agar plates (Merck Co., 
Germany) using the Kirby–Bauer (KB) method as 
suggested by the Clinical and Laboratory 
Standards Institute guideline (CLSI document 
M100-S14).  
The antimicrobial agents were as follows: 
meropenem (10 μg), gentamicin (10 μg), amikacin 
(30 μg), imipenem (10 μg), tobramycin (10 μg), 
tetracycline (30 μg), piperacillin-tazobactam (100-
10 μg), cefepime (30 μg), ceftriaxone (30 μg), 
ampicillin-sulbactam (10-10 μg), and polymyxin B 
(300 μg) (MAST Diagnostics, Merseyside, UK). 
Multidrug-resistant (MDR), extensively drug-
resistant (XDR), and pan-drug-resistant (PDR) 
isolates were detected according to the instruction 
suggested by the Centers for Disease Control and 
Prevention (CDC). Escherichia coli ATCC 25922 
and Acinetobacter baumannii ATCC 19606 were 
used as negative and positive controls, 
respectively. 
Genomic DNA was extracted from A. 
baumannii colonies grown overnight on blood 
agar by Bioneer Co., Korea Kit and used as a 
template for PCR assay. PCR ampliﬁcation was 
done to detect aminoglycoside-(aac(3)-IIa and 
aac(6′)-Ib) and quinolone-(qnrA, qnrB, and qnrS) 
related resistance genes. Amplification of AME 
and PMQR genes was carried out using a thermal 
gradient cycler (Eppendorf Co., Germany) with 
the following protocol: 5 minutes at 94° C for the 
initial denaturation and 36 cycles of amplification 
consisting of 45 seconds at 94°C, 45 seconds at 
52-58°C, and 45 seconds at 72°C, with 5 minutes  
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Table 1. PCR primers and annealing temperatures used in this study. 
Target genes Forward Reverse 
Annealing 
(°C) 
Amplicon size 
(bp) 
qnrA ATTTCTCACGCCAGGATTTG GATCGGCAAAGGTTAGGTCA 58 649 
qnrB GGCTCGAAATTCGCCACTG TTTGCTGTTCGCCAGTCGAA 52 469 
qnrS GCA AGTTCATTGAACAGGGT TCTAAACCGTCGAGTTCGGCG 50 428 
aac(3)-IIa CGGAAGGCAATAACGGAG TCGAACAGGTAGCACTGAG 58 740 
aac(6′)-Ib TTGCGATGCTCTATGAGTGGCTA CTCGAATGCCTGGCGTGTTT 55 611 
 
at 72°C for the final extension. The specific 
primers, temperatures of annealing, and amplicons 
size used for PCR are detailed in Table 1. 
The current survey was a descriptive research. 
The MINITAB16 software was used for statistical 
analyses. The P value and conﬁdence intervals 
were ≤0.05 and 95%, respectively. 
 
Results. One hundred isolates of A. baumannii 
were obtained from different clinical specimens. 
The samples included blood (n=40, 40%), tracheal 
secretion (n=27, 27%), wound (n=12, 12%), urine 
(n=8, 8%), and unknown (n=13, 13%) specimens 
isolated from hospitalized patients in ICU (n=40, 
40%), emergency department (n=20, 20%), and 
infectious disease department (30, 30%), and other 
departments (n=10, 10%). 
The resistance percentage of meropenem, 
gentamicin, amikacin, imipenem, tobramycin, 
tetracycline, piperacillin-tazobactam, cefepime, 
ceftriaxone, ampicillin-sulbactam and polymyxin 
B were 69%, 82%, 63%, 74%, 56%, 51%, 70%, 
97%, 95%, 49%, 3%, respectively (Table 2).  
Antibiotic susceptibility tests using the Kirby-
Bauer method showed that the level of resistance 
to meropenem, gentamicin, amikacin, imipenem, 
tobramycin, tetracycline, piperacillin-tazobactam, 
cefepime, ceftriaxone, ampicillin-sulbactam and 
polymyxin B was 69%, 82%, 63%, 74%, 56%, 
51%, 70%, 97%, 95%, 49%, 3% (Table 2).  
All 100 isolates of the main outbreak strains of 
A. baumannii were PCR positive for blaOXA-51-
like genes. 
Molecular distribution of aminoglycoside 
 
Table 2. Antibiotics resistance profile among A. baumannii 
isolates.  
Antibiotic  
Resistant 
No (%) 
Intermediate 
No (%) 
Sensitive 
No (%) 
Meropenem  69(69%) 16(16%) 15(15%) 
Gentamicin  82(80.4%) 6(5.9%) 14(13.7%) 
Amikacin 63(63%) 10(10%) 27(27%) 
Imipenem  74(76%) 14(14%) 10(10%) 
Tobramycin 56(56%) 7(7%) 37(37%) 
Tetracycline  51(51%) 14(14%) 35(35%) 
Piperacillin-
Tazobactam 
70(70%) 0(0%) 30(30%) 
Cefepime 97(97%) 1(1%) 2(2%) 
Ceftriaxone 95(95%) 5(5%) 0 (0%) 
Ampicillin-
Sulbactam 
49(49%) 17(17%) 34(34%) 
Polymyxin B 3(3%) (0%) 97(97%) 
 
 
Figure 1. A) PCR amplification of the aac(3)-IIa gene. Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control 
(740bp); lane 1, 6, and 7: negative results and lane 2, 3, 4, and 5: positive results. B) PCR amplification of the aac(6′)-Ib gene. Lane M: 
Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (482bp); lane 1-7: positive results. C) PCR amplification of the 
qnrA gene. Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (649bp); lane 1-4, 5, and 7: 
positive results, lane 5: negative result. 
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resistance genes including aac(3)-IIa and aac(6′)- 
Ib were 45% and 50%, respectively is shown in 
the figure 1 A and B. Half of the isolates (50%) 
contained the qnrA (Figure 1C). QnrB and qnrS 
were not found in any strains. Sequencing of PCR 
products for AME and PMQR genes were 
confirmed by BLAST at NCBI. 
 
Discussion. Drug resistance in A. baumannii has 
become a global problem for the severely infected 
patients who critically rely on Antimicrobial 
therapy. The emergence of clinical A. baumannii 
strains with different antibiotic resistance 
phenotypes causes difficulties in treating 
infections caused by this organism.
19,20
 
Multidrug-resistant A. baumannii (MDR-Ab) is 
a subject of profound anxiety as it not only causes 
severe and fatal infections but also increases the 
length of hospital stay, resulting in augmented 
treatment charges.
21
 
In this study, the most antibiotic resistance in A. 
baumannii isolates were related to cefepime 
(97%), ceftriaxone (95%), and amikacin (82%), 
and the most effective drug against these isolates 
was polymyxin B. This data is also valid for 
colistin, which is mostly used in clinics 
worldwide. 
 Henwood et al.,
22
 showed that more than 75% 
of A.baumannii strains were resistant to 
cefotaxime and ceftazidime. In another study, 
Karlowsky et al.,
23
 showed that >90% of A. 
baumannii isolates were susceptible to imipenem 
and meropenem; fewer strains were susceptible to 
amikacin, and <60% were susceptible to 
ceftazidime and gentamicin.  
In agreement with the current study, 
polymyxins, are active agents against the 
overwhelming majority of A. baumannii 
throughout the world. In a systematic review study 
directed by Razavi Nikoo et al.,
24
 polymyxins 
presented adequate activity against A. baumannii 
collected. The frequencies of MDR and XDR 
isolates were 70% and 19% respectively. No PDR 
isolates were identified in this study. 
Hujer et al.
25
 in their study reported that 89% of 
A. baumannii were resistant to at least three 
different classes of antibiotics, and 15% were 
resistant to all antibiotics tested. 
Aminoglycosides are used most commonly in 
the treatment of A. baumannii infections. Most 
enzyme-mediated resistance in A. baumannii is 
due to AMEs encoded genes which found on the 
mobile genetic elements. 
PMQR genes including qnrA, qnrB, and qnrS 
are responsible for quinolone resistance in A. 
baumannii which the prevalence of quinolone-
resistant A. baumannii was increased in recent 
years. In our study, the prevalence rate of PMQR 
genes including qnrA, qnrB, and qnrS was 50%, 
0%, and 0%, respectively. In contrast with our 
data, Chagas et al.,
26
 showed that the prevalence of 
qnrA gene was 37.5% (n=15). The differences 
mentioned above can result from the geographical 
distance, surveillance strategies, and restraint in 
antibiotic prescriptions in other regions. 
 
Conclusions. This study showed that the most 
effective antibiotic against clinical strains of A. 
baumannii was polymyxin B and we recommend 
clinicians to use polymyxins (B or E) in patients 
infected with MDR A. baumannii. However, 
overusing can lead to polymyxin resistance, and 
the drug's toxicity problems should be considered. 
There is a high level of aminoglycoside resistance 
genes among A. baumannii isolates circulating in 
hospitals in Iran. This trend of MDR profiles 
associated with the presence of aac(6′)-Ib and 
aac(3)-IIa genes are worrying. The high 
prevalence rate of these resistance genes highlights 
the necessity for establishing more rapid 
diagnostic assays, more antimicrobial 
susceptibility tests, more clinician-laboratory 
correlation, and continuous monitoring of 
antibiotic resistance due to A. baumannii.  
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